VDPHL01 Meets Primary Endpoint in Women: Positive Phase 2 Results from Study ‘207’
Veradermics, Incorporated (NYSE: MANE) has reported positive topline results from the female treatment arms of Study ‘207’, an open-label Phase […]
News
News
Study 304, Study 306, and the FDA Path: What’s Next for VDPHL01
The April 27, 2026 announcement from Veradermics confirmed what investors and hair loss patients had been waiting months to hear:
News
VDPHL01 Phase 2/3 Trial Results: Early, Robust Hair Growth — and a Clean Safety Record
On April 27, 2026, Veradermics (NYSE: MANE) released positive topline data from Study ‘302’ — the first of two pivotal